(¿Â¶óÀÎ) Á¦26Â÷ ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Ãß°è½ÉÆ÷Áö¾ö : 2020-10-31±³À°ÀÏÀÚ : 2020-10-31
±³À°Àå¼Ò : ¿Â¶óÀÎ ¿¬¼ö±³À° (½Ç½Ã°£ È»ó°ÀÇ/¿Ü±¹ÀÎ ¿¬ÀÚ ³ìÈ°¿¬ ¿µ»ó ¼ÛÃâ)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) Á¦26Â÷ ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Ãß°è½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÇѼ¼¹Ì
¿¬¶ôó : 02-512-0044
À̸ÞÀÏ :
gyncancer@gyncancer.or.kr ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 9 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í Àü¹®ÀÇ 60,000 Àü°øÀÇ 45,000 ÀϹÝÀÇ,¿¬±¸¿ø,°£È£»ç 30,000 ÁÂÀå,¿¬ÀÚ,¸¸65¼¼ÀÌ»ó ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 08:30~08:40 Opening Remarks ±è½Âö(´ëÇѺÎÀÎÁ¾¾çÇÐȸ ȸÀå)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 08:40~08:50 ºÎÀÎÁ¾¾çÀÇÇлó Çмú´ë»ó ¼ö»óÀÚ ³í¹® ¹ßÇ¥ ¹è´ö¼ö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 08:50~09:00 ºÎÀÎÁ¾¾çÀÇÇлó ÀþÀºÀÇÇÐÀÚ»ó ¼ö»óÀÚ ³í¹® ¹ßÇ¥ ±è¿µÅ¹(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 09:00~09:20 The best type of PARPi for the best time in the management of ovarian cancer À̽ÅÈ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 09:20~09:40 The best type of PD1 inhibitor for the best time in the management of cervical cancer ÀÌ¿ø¹«(ÇѾçÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 09:40~10:00 PD1 inhibitor with/without multiple kinase inhibitor for the treatment of endometrial cancer ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 10:00~10:20 Which phase II/III RCTs in ovarian cancer will be finalized in 5 year? À¯ÇåÁ¾(Ãæ³²ÀÇ´ë)
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 10:20~10:30 Discussion ()
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 10:30~10:50 Secondary cytoreductive surgery in recurrent epithelial ovarian cancer ÀÌ ÀÌ»êÈñ(¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 10:50~11:10 Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 11:10~11:30 ADC(Antibody-Drug Conjugate) in management of ovarian cancer Á¶ÇѺ°(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 11:30~11:50 Novel discoverise in endometrial cancer: are we making progress? À̼ºÁ¾(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 11:50~12:10 Screening for lynch syndrome in endometrial cancer patients ±è¹Ì°æ(ÀÌÈÀÇ´ë)
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 12:10~12:20 Discussion ()
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 12:20~12:40 Rationale for earlier intervention with PARP inhibitor and importance of personalized medicine in ovarian cancer ±è±âµ¿(¼¿ïÀÇ´ë)
½Ä»ç 10¿ù 31ÀÏ 12:40~13:40 Lunch ()
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 13:40~14:00 Quality control of surgery in advanced epithelial ovarian cancer Christina Fotopoulou(Imperial College London, UK)
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 14:00~14:05 Discussion ±èÈñ½Â(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 14:05~14:25 Current and future considerations for the use of checkpoint inhibitors in gynecologic cancers David O(The Ohio State University, USA)
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 14:25~14:30 Discussion ¾î°æÁø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 14:30~14:45 An introduction to NUWA-National gynecological oncology research and patient management platform Qinglei Gao(Huazhong University, China)
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 14:45~14:50 Discussion ±è¼¼ÀÍ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 14:50~15:10 9°¡ ÀڱðæºÎ¾Ï ¿¹¹æ¹é½Å Çã°¡ »çÇ× - Áø·á±Ç°í¾È ¾÷µ¥ÀÌÆ® ¹Î°æÁø(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 15:10~15:30 Future treatment strategy based on PARPi frontline ovaian cancer Antonio González-Martín(Clínica Universidad de Navarra, Spain)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 15:30~15:50 Patient blood management as a standard of care ÀÌÁ¤Àç(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 15:50~16:00 Perioperative use of IV iron in gynecologic cancer patients (Áõ·Ê¹ßÇ¥) ¼µ¿ÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 16:00~16:30 Clinical impact of febrile neutropenia with ovarian cancer by pegfilgrastim ÃÖöÈÆ(¼º±Õ°üÀÇ´ë)
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 16:30~16:40 Discussion ()
±âŸ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 13:30~13:40 Opening Remarks ³ëÁÖÈñ(´ëÇѺÎÀÎÁ¾¾çÇÐȸ °£È£ºÐ°ú¼ÒÀ§¿øÀå)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 13:40~14:00 Recent clinical trial outcome based on the hereditary predisposition of gynecologic cancer ½Å¼ÒÁø(°è¸íÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 14:00~14:20 Clinical significance and reclassification of PV/LPV/VUS of BRCA 1/2 ³²ÀºÁö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 14:20~14:40 What should we know about real-world genetic counseling of hereditary gynecologic cancer? Á¤°í¿î(±¹¸³¾Ï¼¾ÅÍ)
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 14:40~14:50 Discussion ()
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 14:50~15:10 Genome & health record È«°æ¿ø(Å׶óÁ¨ÀÌÅؽº)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 15:10~15:30 New treatment for hereditary gyencologic cancer À¯¼±¿µ(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 15:30~15:50 Knowledge and anxiety in heritage ovarian cancer patients ÀÌ»óÈñ(±¹¸³¾Ï¼¾ÅÍ)
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 15:50~16:00 Discussion ()
±âŸ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 16:40~16:50 Closing Remarks ()
±âŸ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ZOOM Meeting) 16:50~17:00 Á¤±âÃÑȸ (ZOOM Meeting) ()